Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from “Idea to IND” (“I to ITM”), announced today that the Company will attend the 14th Protein and Antibody Engineering Summit (PEGS) in Barcelona, Spain, November 14-16, 2022. The booth will be located at #54.
Frank Grosveld, Ph.D., the scientific founder of Nona Biosciences, will give a presentation on the Company’s fully human transgenic mouse antibody platform and the one-stop antibody development service capabilities.
Nona Biosciences has groundbreakingly launched its “Open Access” business model - in order to remove the technology barrier for potential partners, and to enable the platform and technology to truly empower the discovery and development of next-generation innovative therapeutics worldwide. Frank Grosveld will elaborate further on the innovative business model and the biological strengths of Nona Biosciences at the summit.
Nona Biosciences (a wholly-owned subsidiary of HBM Holdings, HKEX: 02142) is a global biotechnology company committed to providing a total solution from “Idea to IND” (“I to ITM”), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.
Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. More information, please check www.nonabio.com